海普瑞(002399.SZ)擬向美國海普瑞增資不超6.9895億元
格隆匯 7 月 31日丨海普瑞(002399.SZ)公佈,Hepalink USA Inc.(“美國海普瑞”)系公司的全資子公司,投資額為約1.13億美元。為了改善美國海普瑞的資產負債結構以降低其財務費用,並增強其作為公司海外投資平台的資本實力,公司擬以自有資金摺合不超過人民幣6.9895億元增加對美國海普瑞的投資(根據2020年7月28日人民幣兑美元匯率6.9895計算),此次增資完成後,美國海普瑞的投資總額將增加至不超過約2.13億美元,仍為公司的全資子公司。
此次對美國海普瑞的增資主要是為了改善美國海普瑞的資產負債結構,降低其銀行貸款的財務費用支出,並增加其未來的融資與投資能力,將進一步強化其作為公司海外投資業務發展和技術引進的平台作用。增資完成後,美國海普瑞仍為公司的全資子公司,不影響公司合併報表範圍,對公司正常經營沒有影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.